FDA approves herbal medicine for COVID-19 treatment

The Food and Drugs Authority (FDA) of Ghana has approved a herbal medicine known as Cryptolepis Sanguinolenta for clinical trial of COVID-19 treatment. 

In a statement, FDA disclosed that the herbal medicine was submitted by the “School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020.”

“The Food and Drugs Authority (FDA), The National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”

“In the search for a treatment for the ongoing COVID-19 pandemic, researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for COVID-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits.”

Read the full statement below: